Title |
Chimeric Antigen Receptor Therapy for Cancer
|
---|---|
Published in |
Annual Review of Medicine, November 2013
|
DOI | 10.1146/annurev-med-060512-150254 |
Pubmed ID | |
Authors |
David M. Barrett, Nathan Singh, David L. Porter, Stephan A. Grupp, Carl H. June |
Abstract |
Improved outcomes for patients with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, synthetic biology, and cell-processing technologies has paved the way for clinical applications of chimeric antigen receptor-based therapies. This new form of targeted immunotherapy merges the exquisite targeting specificity of monoclonal antibodies with the potent cytotoxicity and long-term persistence provided by cytotoxic T cells. Although this field is still in its infancy, clinical trials have already shown clinically significant antitumor activity in neuroblastoma, chronic lymphocytic leukemia, and B cell lymphoma, and trials targeting a variety of other adult and pediatric malignancies are under way. Ongoing work is focused on identifying optimal tumor targets and on elucidating and manipulating both cell- and host-associated factors to support expansion and persistence of the genetically engineered cells in vivo. The potential to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be made opens up an entirely new arena for targeted therapy of cancer. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 29% |
Unknown | 5 | 71% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 3 | 43% |
Members of the public | 3 | 43% |
Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | <1% |
Germany | 3 | <1% |
United Kingdom | 3 | <1% |
Belgium | 2 | <1% |
Japan | 2 | <1% |
Netherlands | 1 | <1% |
Brazil | 1 | <1% |
Slovenia | 1 | <1% |
Malaysia | 1 | <1% |
Other | 2 | <1% |
Unknown | 511 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 118 | 22% |
Researcher | 106 | 20% |
Student > Bachelor | 67 | 13% |
Student > Master | 59 | 11% |
Other | 26 | 5% |
Other | 83 | 16% |
Unknown | 72 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 159 | 30% |
Biochemistry, Genetics and Molecular Biology | 87 | 16% |
Medicine and Dentistry | 75 | 14% |
Immunology and Microbiology | 58 | 11% |
Engineering | 18 | 3% |
Other | 51 | 10% |
Unknown | 83 | 16% |